Skip to main content
Full access
Letters to the Editor
Published Online: 1 May 2018

Comment on Late-Onset ADHD Reconsidered With Comprehensive Repeated Assessments Between Ages 10 and 25

To the Editor: We read with great interest the article by Sibley et al. (1), published in the February 2018 issue of the Journal, examining symptoms of attention deficit hyperactivity disorder (ADHD) longitudinally in a cohort without a baseline childhood diagnosis.
The authors identified cases of possible late-onset ADHD via screening and then used an iterative process to rule out nontrue cases. The overwhelming majority did not have true late-onset adult ADHD but had childhood symptoms persisting into adulthood, or they did not have ADHD (rather, they had cognitive impairment due to heavy substance use or other psychiatric morbidities).
These U.S. findings accord closely with our experience in U.K. adult ADHD clinics. We have not observed a single case of true adult-onset ADHD. The authors’ findings (1) support the need for specialist assessment by experienced ADHD clinicians. Screening instruments are blunt tools, potentially helpful for initial gate-keeping but not for confirming or refuting an ADHD diagnosis or for teasing apart nuanced differences from or overlap with other disorders.
Sibley and colleagues identified two adults with late-onset ADHD where the diagnosis may have been valid (i.e., there was an absence of childhood symptoms, and symptoms were not due to heavy substance use or other identified mental disorders). We wonder whether these uncommon cases may reflect organic pathology, such as cognitive dysfunction from thyroid disease or traumatic brain injury (diffuse axonal injury can give normal results on a brain scan) or other psychiatric disorders (e.g., impulse control disorders or gambling disorder, which are not typically screened for).
In the United Kingdom, there is a lack of National Health Service resourcing for adult ADHD. As Sibley et al. acknowledge, decades of research support ADHD as a chronic neurodevelopmental condition that often persists into adulthood (1). Recent DSM changes allow for the diagnosis of some high-functioning adult cases. The lack of resource provision in the United Kingdom is extremely unfortunate given ADHD’s high prevalence, coupled with the existence of clinically effective, cost-effective treatments. ADHD treatment may reduce criminality and driving accidents (2, 3). For those with ADHD treated appropriately, patients often report profound benefits for everyday functioning.

References

1.
Sibley MH, Rohde LA, Swanson JM, et al: Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. Am J Psychiatry 2018; 175:140–149
2.
Lichtenstein P, Halldner L, Zetterqvist J, et al: Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367:2006–2014
3.
Gobbo MA, Louzã MR: Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: a systematic review. Eur Neuropsychopharmacol 2014; 24:1425–1443

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 480
PubMed: 29712469

History

Accepted: February 2018
Published online: 1 May 2018
Published in print: May 01, 2018

Keywords

  1. Attention Deficit Hyperactivity Disorder
  2. Epidemiology
  3. Diagnosis And Classification

Authors

Details

Samuel R. Chamberlain, M.B.B.Chir. (Dr. Med.), Ph.D. [email protected]
From the Department of Psychiatry, University of Cambridge, Cambridge, U.K.; the Adult ADHD Service, Cambridge and Peterborough NHS Foundation Trust, Cambridge, U.K.; and the Adult ADHD Service, Barnet Enfield Haringey NHS Mental Health Trust, London.
Ulrich Müller, M.D. (Dr. Med.), Ph.D.
From the Department of Psychiatry, University of Cambridge, Cambridge, U.K.; the Adult ADHD Service, Cambridge and Peterborough NHS Foundation Trust, Cambridge, U.K.; and the Adult ADHD Service, Barnet Enfield Haringey NHS Mental Health Trust, London.

Notes

Address correspondence to Dr. Chamberlain ([email protected]).

Funding Information

Wellcome Trust10.13039/100004440: 110049/Z/15/Z
Dr. Chamberlain’s research has been funded by a clinical fellowship from the Wellcome Trust (reference 110049/Z/15/Z).Dr. Chamberlain is a consultant for Cambridge Cognition and Shire. Dr. Müller has received speakers and consultancy honoraria and/or travel expenses from the British Association for Psychopharmacology, Eli Lilly, Flynn Pharma, Heptares, Medice, Shire, and the U.K. Adult ADHD Network.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share